At Bachem, we believe in open and transparent dialogue with both the financial community and public media.
As a company listed on the Swiss stock exchange, we provide regular information on the strategy and current situation of our company as well as on planned and expected future developments.
On these pages, we have compiled the most important information for shareholders and representatives of the capital markets as well as for media representatives, and we update it regularly.
Your contact at Bachem for investor and media enquiries:
Dr. Daniel Grotzky
Head Group Communications
Bachem Holding AG
Hauptstrasse 144
4416 Bubendorf
Switzerland
Tel +41 58 595 2021 (Direct: -3806)
Investor enquiries: ir@bachem.com
Media enquiries: media@bachem.com
Please state your outlet (financial institution or media outlet) and any relevant deadline for information when reaching out to us.
Subscribe
to our press releases and investor news
Click here >>
Latest financial news
- All
- Ad-hoc
- Finance
Bachem achieves solid growth in 2022
Bachem signs long-term cooperation agreement for the development and supply of peptides
Bachem signs long-term follow-on contract for peptides
Corporate governance
Board of Directors
Bachem’s Board of Directors are responsible for defining the corporate strategy and are elected by the company shareholders.
Corporate Executive Committee
Responsible for managing Bachem worldwide and for implementing policies and strategies as defined by the Board of Directors.
Code of Conduct
The basis for the behavior which we demonstrate day by day. This Code of Conduct forms an integral part for everyone at Bachem.
Statuten /
Articles of Association of Bachem Holding AG
Analyst coverage
As a stock listed company, Bachem is as a company reviewed and commented upon by analysts on a regular basis. According to our best knowledge, the hereunder mentioned finance institutions prepare and issue Bachem related reports. There is no guarantee regarding the completeness and correctness of the list, although we strive to maintain and update it. Bachem does not comment on any analyst report and disclaims any liability in relation with statements or recommendations made therein as well as transactions based thereon.
Analysts
Vontobel
Sibylle Bischofberger,
Senior Analyst Equity Research
sibylle.bischofberger@vontobel.com
+41 58 283 70 21
Credit Suisse AG
tanya hansalik,
securities Research emea Switzerland
tanya.hansalik@credit-suisse.com
+41 44 334 22 10
Mirabaud Securities Limited
Dr. Anja Pomrehn,
Senior Medical Technology and Chemical Equity Analyst
anja.pomrehn@mirabaud-msl.com
+41 44 798 24 68
Research Partners AG
Dr. Martin Vögtli
martin.voegtli@researchpartners.ch
+41 44 533 40 30
Zürcher Kantonalbank
Daniel Buchta, MSc
daniel.buchta@zkb.ch
+41 44 292 37 34
Octavian AG
LAURA pfeifer-rossi
laura.pfeifer-rossi@octavian.ch
+41 44 520 06 29
Stifel Schweiz AG
Daniel Jelovcan,
Managing Director
Medtech & Life Science chemicals
daniel.jelovcan@stifel.com
+41 43 888 6108
UBS
Barbora Blaha
barbora.blaha@ubs.com
+41 44 238 95 61
Baader Helvea AG
Konstantin Wiechert,
Analyst Equity Research
kwiechert@helvea.com
+41 43 388 9213
Contact us